Purpose Limited information is available on the impact of chemotherapy (CTX)-induced neurotoxicity on adult survivors' symptom experience and quality of life (QOL). Purposes were to describe occurrence of hearing loss and tinnitus and evaluate for differences in phenotypic characteristics and measures of sensation, balance, perceived stress, symptom burden, and QOL between survivors who received neurotoxic CTX and did (i.e., neurotoxicity group) and did not (i.e., no neurotoxicity group) develop neurotoxicity. Neurotoxicity was defined as the presence of chemotherapyinduced neuropathy (CIN), hearing loss, and tinnitus. Survivors in the no neurotoxicity group had none of these conditions. Methods Survivors (n = 609) completed questionnaires that evaluated hearing loss, tinnitus, stress, symptoms, and QOL. Objective measures of sensation and balance were evaluated. Results Of the 609 survivors evaluated, 68.6% did and 31.4% did not have CIN. Of the survivors without CIN, 42.4% reported either hearing loss and/or tinnitus and 48.1% of the survivors with CIN reported some form of ototoxicity. Compared to the no neurotoxicity group (n = 110), survivors in the neurotoxicity group (n = 85) were older, were less likely to be employed, had a higher comorbidity burden, and a higher symptom burden, higher levels of perceived stress, and poorer QOL (all p < .05). Conclusions Findings suggest that CIN, hearing loss, and tinnitus are relatively common conditions in survivors who received neurotoxic CTX. Implications for cancer survivors Survivors need to be evaluated for these neurotoxicities and receive appropriate interventions. Referrals to audiologists and physical therapists are warranted to improve survivors' hearing ability, functional status, and QOL.
Introduction
Given that by January 2024, the number of cancer survivors in the USA will total 19 million [1] , organizations like the National Comprehensive Cancer Network (NCCN) developed guidelines for adult cancer survivors [2] . While pain is addressed in these guidelines, little information is provided on the assessment and management of chemotherapy-induced neuropathy (CIN). In addition, the guideline is silent on any evaluation of the deleterious effects of neurotoxic chemotherapy (CTX) on the audiovestibular system (i.e., hearing loss, tinnitus, disturbances in balance).
Research on hearing loss associated with neurotoxic CTX has focused primarily on pediatric patients who received platinum [3] [4] [5] . The limited amount of work in adults focused on hearing loss in patients receiving platinum for testicular or head and neck cancer. Across these studies, platinum induced a bilateral and symmetrical sensorineural hearing loss [6] . Compared to testicular [7] [8] [9] [10] and head and neck [11, 12] cancer, only a few case reports and small studies provide inconclusive findings on hearing loss in patients with breast, gastrointestinal (GI), gynecological (GYN), or lung cancer [13] [14] [15] [16] [17] [18] . Even less is known about the occurrence and impact of hearing loss associated with taxanes. In fact, no large-scale study has evaluated the impact of hearing loss in adult survivors of breast, GI, GYN, or lung cancer who received a platinum and/or taxane-containing CTX regimen.
Tinnitus is the awareness of an auditory percept in the absence of an external stimulus. Typically, these percepts are described as hissing, buzzing, and ringing [19] . In patients with testicular cancer, who received cisplatin, tinnitus rates ranged from 19 to 42% [20] . In the one study of 41 ovarian cancer patients who received platinum, tinnitus was reported by 27% of the women [18] . Again, no studies have described the occurrence or impact of tinnitus in adult survivors of breast, GI, or lung cancer who received a platinum and/or a taxane compound.
Stress may be a common underlying mechanism for CIN [21] and tinnitus [22, 23] . Increased stress exacerbates both conditions and evidence suggests that patients with pain [24, 25] and tinnitus [26, 27] have alterations in autonomic processing. However, no studies were found that evaluated associations between perceived stress and any of the neurotoxic effects (i.e., CIN, hearing loss, tinnitus) of CTX.
Given that breast, GI, GYN, and lung cancers are the four most common oncologic diagnoses in adults and platinum and taxane compounds are the mainstay of treatment for these cancers, an evaluation of the occurrence and impact of hearing loss and tinnitus in adult cancer survivors is warranted at the present time. Therefore, the purposes of this study were to describe the occurrence of hearing loss and tinnitus and to evaluate for differences in demographic and clinical characteristics, as well as measures of sensation, balance, perceived stress, symptom burden, and quality of life (QOL) between survivors who received a platinum and/or a taxane compound and did (i.e., neurotoxicity group) and did not (i.e., no neurotoxicity group) develop neurotoxicity. For the purposes of this paper, neurotoxicity is defined as the presence of CIN, hearing loss, and tinnitus. Survivors in the no neurotoxicity group had none of these conditions.
Methods

Survivors and settings
The methods for this larger study are described in detail elsewhere [28] . In brief, a convenience sample of survivors was recruited from throughout the San Francisco Bay area using the following strategies: direct referral from clinicians; direct mailing to survivors who were identified through targeted searches of our medical center's electronic health record; newspaper advertisements; emails to participants in the Dr.
Susan Love Research Foundation's Army of Women® Program; emails to support group members; postings on survivorship websites; postings on ClinicalTrials.gov; presentations at support group meetings; and snowball sampling through referrals from survivors. Survivors with CIN met the following inclusion criteria: were ≥ 18 years of age; had received a platinum and/or a taxane compound; had completed their course of CTX ≥ 3 months prior to enrollment; had changes in sensation and/or pain in their feet and/ or hands of ≥3 month s duration following the completion of CTX; had a rating of ≥ 3 on a 0 to 10 numeric rating scale (NRS) for any one of the following sensations from the Pain Quality Assessment Scale (i.e., numb, tender, shooting, sensitive, electrical, tingling radiating, throbbing, cramping, itchy, unpleasant) [29] ; if they had pain associated with the CIN, had an average pain intensity score in their feet and/or hands of ≥ 3 on a 0 to 10 NRS; had a Karnofsky Performance Status (KPS) score of ≥ 50; and were able to read, write, and understand English.
Survivors without CIN met the following inclusion criteria: were ≥ 18 years of age; had received a platinum and/or a taxane compound; had completed their course of CTX ≥ 3 months prior to enrollment; did not have persistent changes in sensation and/or pain in their hands or feet at the time of enrollment; had a KPS score of ≥ 50; and were able to read, write, and understand English.
Survivors with and without CIN were excluded if they had: peripheral vascular disease, vitamin B 12 deficiency, thyroid dysfunction, HIV neuropathy, another painful condition that was difficult for them to distinguish from their CIN, a hereditary sensory or autonomic neuropathy, and/or a hereditary mitochondrial disorder. Of the 1450 survivors who were screened, 754 were enrolled, and 609 completed the selfreport questionnaires and the study visit. This paper focuses on a subset of this sample (i.e., those without neurotoxicity (n = 110) and those with all three neurotoxicities (n = 85)).
Study procedures
Research nurses screened and consented the survivors over the phone; sent and asked them to complete the self-report questionnaires prior to their study visit; and scheduled the in-person assessment. At this assessment, written informed consent was obtained, questionnaires were reviewed for completeness, and objective measurements were done.
Study measures
Demographic and clinical characteristics Survivors provided information on demographic characteristics and completed the KPS scale [30] [31] [32] and the Self-Administered Comorbidity Questionnaire (SCQ) [33, 34] .
Hearing loss and tinnitus Two items from the Functional Assessment of Therapy/Gynecologic Oncology Group Neurotoxicity (FACT/GOG-Ntx) subscale were used to evaluate hearing loss (i.e., I have trouble hearing) and tinnitus (i.e., I get ringing or buzzing in my ears) [35] . Each item was rated on a 0 (not at all) to 4 (very much) scale. Survivors who reported a 0 for either of these questions were classified as not having that neurotoxic effect.
Sensation Light touch was evaluated using SemmesWeinstein monofilaments [36] . Cold sensation was evaluated using the Tiptherm Rod [37, 38] . Pain sensation was evaluated using the Neurotip [38] . Vibration threshold was assessed using a vibrometer [39] . For all of the measures of sensation, both the upper and lower extremities on the dominant side were tested.
Balance Self-report questions from the chemotherapyinduced peripheral neuropathy assessment tool (CIPNAT) were used to assess balance [40] . The objective measures of balance were the timed get up and go test (TUG) [41] and the Fullerton Advanced Balance (FAB) test [42, 43] . The TUG test is a timed test of a person's ability to stand from an armed chair, walk 10 ft, turn, and return to a seated position [41] . Survivors were instructed to walk as quickly as possible, without running. The time needed to perform the test was recorded.
The FAB is a measure of balance that includes ten tasks: standing with feet together and eyes closed, reaching forward to retrieve a pencil held at shoulder height, turning 360 o in a right then in a left direction, stepping up and over a 15.2 cm (6 in. bench, tandem walking, standing on one leg, standing on foam with eyes closed, 2-footed jumping for a distance, walking with head turns, and responding to an unexpected trunk perturbation [42, 43] . The FAB was chosen because the tasks challenge the sensory systems (i.e., visual, somatosensory, vestibular) used for postural control that may be more sensitive to balance problems in individuals with CIN, a primary sensory neuropathy. The quality of the performance of each task is scored using standardized ordinal scoring criteria. Total scores can range from 0 to 40. Higher scores indicate a better performance.
Symptom burden Survivors completed self-report questionnaires that evaluated trait and state anxiety [44] , depressive symptoms [45] , diurnal variations in fatigue and energy [46] , sleep disturbance [47] , and changes in attentional function [48] .
The Spielberger State-Trait Anxiety Inventories (STAI-S and STAI-T) each have 20 items that are rated from 1 to 4. The summed scores for each scale can range from 20 to 80. The STAI-T measures a person's predisposition to anxiety as part of one's personality. The STAI-S measures a person's temporary anxiety response to a specific situation or how anxious or tense a person is Bright now^in a specific situation. Cutoff scores of ≥ 31.8 and ≥ 32.2 indicate high levels of trait and state anxiety, respectively. The STAI-T and STAI-S inventories have well established validity and reliability [44] . In our study, the Cronbach's alphas for the STAI-T and STAI-S were 0.91 and 0.95, respectively.
The Center for Epidemiological Studies-Depression (CES-D) scale consists of 20 items selected to represent the major symptoms in the clinical syndrome of depression. A total score can range from 0 to 60, with scores of ≥ 16 indicating the need for individuals to seek clinical evaluation for major depression. The CES-D has well established validity and reliability [45] . In our study, the Cronbach's alpha for the CES-D total score was 0.86.
The 18-item Lee Fatigue Scale (LFS) assessed physical fatigue and energy [46] . Each item was rated on a 0 to 10 numeric rating scale (NRS). Total fatigue and energy scores were calculated as the mean of the 13 fatigue items and the 5 energy items, respectively. Higher scores indicate greater fatigue severity and higher levels of energy. Using separate LFSs, patients rated each item based on how they felt within 30 min of awakening (i.e., morning fatigue, morning energy) and prior to going to bed (i.e., evening fatigue, evening energy). The LFS has established cutoff scores for clinically meaningful levels of fatigue (i.e., ≥ 3.2 for morning fatigue, ≥ 5.6 for evening fatigue) [49] and energy (i.e., ≥ 6.2 for morning energy, ≥ 3.5 for evening energy) [49] . In our study, the Cronbach's alphas were 0.96 for morning and 0.94 for evening fatigue and 0.95 for morning and 0.93 for evening energy.
The General Sleep Disturbance Scale (GSDS) consists of 21 items designed to assess the quality of sleep in the past week. Each item was rated on a 0 (never) to 7 (everyday) NRS. A GSDS total score of ≥ 43 indicates a significant level of sleep disturbance [49] . The GSDS has well-established validity and reliability [47, 50] . In our study, the Cronbach's alpha for the GSDS total score was 0.85.
The Attentional Function Index (AFI) consists of 16 items designed to measure attentional function [48] . A higher total mean score on a 0 to 10 NRS indicates greater capacity to direct attention [48] . Total scores are grouped into categories of attentional function (i.e., < 5.0 low function, 5.0 to 7.5 moderate function, > 7.5 high function) [51] . The AFI has well-established validity and reliability [48] . In our study, the Cronbach's alpha for the total AFI score was 0.92.
Stress Survivors completed the Perceived Stress Scale [52] and the Impact of Event Scale-Revised [53, 54] .
The PSS is a 14-item instrument that provides a global evaluation of perceived stress due to life circumstances appraised as stressful over the course of the past week. [52] Each item was rated on a 0 to 4 Likert scale (i.e., 0 = never, 1 = almost never, 2 = sometimes, 3 = fairly often, 4 = very often). Seven out of the 14 items of PSS-14 are considered negative and the remaining seven are positive. Total scores are calculated after reversing the positive items' scores and then summing up all scores. Total scores for PSS-14 can range from 0 to 56. A higher score indicates greater stress. The PSS has well-established validity and reliability [55] . In this study, its Cronbach's alpha was 0.91.
The IES-R is a 22-item instrument that was used to measure distress associated with cancer and its treatment [53, 54] . Patients rated each item based on how distressing each potential difficulty was for them during the past week Bwith respect to their cancer and its treatment^. Each item was rated on a 0 to 4 Likert scale (i.e., 0 = not at all, 1 = a little bit, 2 = moderately, 3 = quite a bit, 4 = extremely). Three subscales are created using the mean of the responses. These mean scores allow the user to identify the degree of symptomatology because the subscale scores are presented on the same metric as the item responses. A total score is created by summing the responses to the 22 items. The three subscales evaluate the level of intrusion (eight items), avoidance (eight items), and hyperarousal (six items) perceived by patient. The total score can range from 0 to 88. For the total score, a cutoff is set at 33, while a score between 24 and 29 is taken as a sign of a partial PTSD and a score of ≥ 37 indicates a high presence of post-traumatic symptomatology [56] . The IES-R has well-established validity and reliability [56] [57] [58] . In this study, the Cronbach's alpha for the IES-R total score was 0.92.
QOL A generic evaluation of QOL was done using the Medical Outcomes Study-Short Form (SF-12) [59] . The disease-specific measure of QOL was the QOL scale-patient version (QOL-PV) [60] [61] [62] [63] .
The SF-12 consists of 12 questions about physical and mental health as well as overall health status. The SF-12 was scored into two components that measure physical (i.e., physical component summary (PCS)) and psychological (mental component summary (MCS)) function. These scores can range from 0 to 100. Higher PCS and MCS scores indicate better physical and psychological functioning, respectively. The individual items on the SF-12 were used to evaluate generic aspects of QOL. The SF-12 has well-established validity and reliability [59] .
The QOL-PV consists of 41 items that measure four domains of QOL (i.e., physical, psychological, social, and spiritual well-being) in oncology patients, as well as a total QOL score. Each item is rated on a 0 to 10 NRS with higher scores indicating a better QOL. The QOL-PV has well-established validity and reliability [60] [61] [62] [63] . In the current study, the Cronbach's alpha for the QOL-PV total score was 0.92.
Data analysis
Data were analyzed using SPSS version 23 [64] . Descriptive statistics and frequency distributions were calculated for survivors' demographic and clinical characteristics. For the four measures of sensation (i.e., light touch, cold, pain, vibration), composite scores, over all of the sites that were tested on the dominant upper and lower extremities, were created. For light touch, cold, and pain, the number of sites with loss of each sensation was summed. For vibration, the mean score across the sites was calculated. Differences between the neurotoxicity and no neurotoxicity groups in phenotypic characteristics, balance, and levels of perceived stress, symptom burden, and QOL were evaluated through bivariate analyses using Independent sample t tests, chi-square analyses, and MannWhitney U tests. A p value of < .05 was considered statistically significant.
Results
Occurrence of neurotoxicity In this sample of 609 survivors, 68.6% did and 31.4% did not have CIN. The distribution of hearing loss and tinnitus among the 609 survivors is illustrated in Fig. 1 . For this paper, differences between the 110 survivors without neurotoxicity (i.e., neither CIN, nor hearing loss, nor tinnitus; 18.1% of the total sample) and the 85 survivors with neurotoxicity (i.e., CIN, hearing loss, and tinnitus; 14.0% of the total sample) were evaluated.
Differences in demographic and clinical characteristics
As shown in Table 1 , survivors with neurotoxicity were significantly older (p = .001) and were more likely to be unemployed (p = .006), more likely to report a lower annual household income (p < .001), and more likely not to have child care responsibilities (p = .001). In terms of clinical characteristics (see Table 2 ), survivors with neurotoxicity had: a higher BMI (p = .011); a higher number of comorbidities (p < .001) and worse comorbidity profile (p < .001); a lower KPS score (p < .001) and received fewer cancer treatments. In addition, these survivors were more likely to report osteoarthritis (p < .001), back pain (p < .001), depression (p = .006), and kidney disease (p = .003); were more likely to have had a dose reduction or delay due to CIN (p = .011); and were less likely to exercise on a regular basis (p = .003). Of note, no between group differences were found in the years since the cancer diagnosis, number of metastatic sites, type of CTX regimen administered, and doses of platinum and/or taxane compounds received.
Differences in sensation
Survivors in the neurotoxicity group had a higher number of upper and lower extremity sites with loss of light touch, cold, and pain sensations (all, p < .001). For both the upper and lower extremities, vibration thresholds were significantly higher in the neurotoxicity group (both, p < .001, Table 3 ).
Differences in balance
Survivors in the neurotoxicity group were more likely to report trouble with balance (p < .001) as well as higher severity (p < .001), frequency (p < .001), and distress (p = .002) scores associated with balance problems (see Table 3 ). In addition, these survivors reported worse TUG (p < .001) and worse FAB (p < .001) scores. 
Differences in symptom burden
Except for evening fatigue, survivors in the neurotoxicity group reported higher scores for trait and state anxiety (both p < .001), depressive symptoms (p < .001), morning fatigue (p = .003), and sleep disturbance (p < .001). In addition, these survivors reported lower levels of morning (p = .003) and evening (p = .018) energy, and worse attentional function scores (p < .001). 
Differences in perceived stress
Except for the IES-R avoidance subscale, survivors in the neurotoxicity group reported higher IES-R subscale (both p < .001) and total (p = .001) scores and a higher PSS (p < .001) score.
Differences in QOL
For all of the SF-12 subscale scores, as well as for the PCS and MCS scores, survivors in the neurotoxicity group reported lower scores (all p < .001, except for the MCS score (p = .004)). Except for the spiritual well-being subscale, the same group differences were seen for the subscale and total scores on the QOLS-PV (all p < .001).
Discussion
This study is the first to provide occurrence data on ototoxicity (i.e., hearing loss and tinnitus) in adult cancer survivors with and without CIN and to evaluate for differences in demographic and clinical characteristics, as well as important outcomes, in survivors with and without neurotoxicity. In this large, convenience sample, 81 of the 191 adult survivors without CIN (42.4%) reported hearing loss and/or tinnitus. In the 418 survivors with CIN, 201 (48.1%) reported some form of ototoxicity. While previous studies of survivors with testicular [10] and ovarian [18] cancer evaluated only individuals who received a platinum compound and did not include CIN in their phenotyping, their occurrence rates for hearing and tinnitus were relatively similar to our findings. While CIN is assessed by most oncologists, these data suggest k At its worst, how severe is the trouble with your balance (0 = not at all severe to 10 = extremely severe)?
l How often do you have trouble with your balance (0 = never to 10 = always)?
m At its worst, how distressing is the trouble with your balance (0 = not at all distressing to 10 = extremely distressing)?
that ongoing audiologic evaluations for hearing and tinnitus are warranted during and following neurotoxic CTX.
In terms of differences in demographic and clinical characteristics, survivors in the neurotoxicity group were more likely to be older, not employed, and have a lower annual household income. While no studies of adult cancer survivors were identified, the association between increasing age in the general population and hearing loss is known [65] .
In terms of clinical characteristics, while findings from previous studies suggest that ototoxicity occurs in a dosedependent manner [6] , no between group differences were found in the distribution of the CTX regimens or in the total doses of the platinum and/or taxane compounds administered (Table 2 ). However, while the absolute numbers in this sample were relatively small, a higher percentage of survivors in the neurotoxicity group had a dose reduction or delay in their CTX treatment. In a similar manner, 8.2% of the survivors in the neurotoxicity group reported kidney disease as a concurrent comorbidity. Overall, survivors in the neurotoxicity group had a worse comorbidity profile and a poorer functional status. Again, cross-sectional studies of the general population found that adults with hearing loss and/or tinnitus report a more severe comorbidity profile, particularly anxiety and depression, as well as poorer functional outcomes [66] [67] [68] [69] .
As expected, all of the measures of sensation were significantly worse in the neurotoxicity group. Overall decrements in all sensations were worse in the lower extremity than in the upper extremity. Clinicians need to assess for losses in protective sensations associated with CIN and educate patients to employ strategies to prevent injuries to their hands and feet.
Recent evidence suggests that balance problems and falls are a significant problem for survivors with CIN [70] . Of note, all of the self-report data and objective measures of balance were significantly worse in the neurotoxicity group. The impact and consequences of these balance problems warrant investigation in future studies.
As shown in Table 3 , with the exception of evening fatigue, all of the other symptom severity scores were higher in the neurotoxicity group. In addition, except for depressive symptoms, all of the symptom severity scores in the neurotoxicity group were above the clinically meaningful cut-off scores. While the relative contribution of CIN versus hearing loss versus tinnitus to the symptom burden of these survivors warrants additional investigation, our findings suggest that clinicians need to assess for multiple symptoms and initiate appropriate symptom management interventions.
While previous research demonstrates positive associations between stress and pain [24, 25] , as well as tinnitus [26, 27] , our study is the first to suggest that survivors with neurotoxicity have higher levels of both generic and disease/ treatment-related stress. The PSS is a widely used measure that evaluates non-specific stress that exceeds a person's coping abilities [52] . While no clinically meaningful cut-off score for the PSS exists, the patients with neurotoxicity had significantly higher scores. Our PSS scores are comparable to those reported by breast (i.e., 11.6 (±7.9)) [71] and prostate (i.e., 17.9 (±8.1)) [72] cancer survivors. In terms of the IES-R, which is designed to measure an individual's response to a specific traumatic event (i.e., cancer and its treatment) [54] , while neither group exceeded the clinically meaningful cutoff score of ≥ 33, survivors with neurotoxicity reported higher scores for the intrusion and hyperarousal subscales as well as for the total IES-R score. In addition, while only one survivor (.01%) in the no neurotoxicity group reported a total IES-R score above the cut-off, 14survivors (16.7%) in the neurotoxicity group reported total IES-R scores that ranged from 33 to 76.
Recent reviews on cancer survivorship suggest that a higher symptom burden is associated with significant decrements in the various domains of QOL [73] [74] [75] . However, no studies were identified that evaluated for differences in QOL outcomes between survivors with and without CTX-induced neurotoxicity. In our study, except for the spiritual well-being subscale of the QOLS-PV, the neurotoxicity group reported not only statistically significant but clinically meaningful (i.e., Cohen's d = 0.43 to 0.96) decrements in the physical, psychological, and social domains of QOL (see Table 3 ) [76, 77] . It should be noted that for both the PCS and MCS subscales of the SF-12, the neurotoxicity group had scores of below 50 which is the normative score for the general US population [59] . Future studies need to evaluate the relative contribution of each neurotoxicity to these significant decrements in QOL.
A number of limitations warrant consideration. While pretreatment hearing loss and tinnitus were not assessed and a detailed clinical evaluation of hearing loss and tinnitus was not performed, our data suggest that survivors' self-reports of these two conditions can assist clinicians to determine the need for additional tests. While only survivors who received a platinum and/or a taxane compound were evaluated, other CTX drugs produce neurotoxicity. Therefore, our findings may not generalize to survivors who received other types of neurotoxic CTX.
Despite these limitations, our findings suggest that CIN, hearing loss, and tinnitus are relatively common conditions in adult cancer survivors who received a platinum and/or a taxane compound. In addition, survivors with all three of these conditions experience an extremely high symptom burden and significant decrements in QOL. Additional research is warranted to evaluate the common and distinct mechanisms associated with these three conditions; their mechanistic relationships with stressful life events; as well as the impact of these three conditions on balance, risk for falls, and physical activity. In the interim, clinicians who care for adult survivors who received neurotoxic CTX need to assess for these three conditions and initiate appropriate referrals for a more complete audiometric evaluation of hearing loss and tinnitus. In addition, referrals to physical and occupational therapists are warranted to assist survivors to deal with the loss of protective sensations and problems with balance.
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